These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 31705824)

  • 1. Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
    Unalp-Arida A; Ruhl CE
    Hepatology; 2020 Mar; 71(3):820-834. PubMed ID: 31705824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis.
    Valenti L; Maggioni P; Piperno A; Rametta R; Pelucchi S; Mariani R; Dongiovanni P; Fracanzani AL; Fargion S
    World J Gastroenterol; 2012 Jun; 18(22):2813-20. PubMed ID: 22719190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
    Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
    Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
    Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY
    World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PNPLA3 gene polymorphism and overall and cardiovascular mortality in the United States.
    Wijarnpreecha K; Scribani M; Raymond P; Harnois DM; Keaveny AP; Ahmed A; Kim D
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1789-1794. PubMed ID: 32220085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
    Krawczyk M; Jiménez-Agüero R; Alustiza JM; Emparanza JI; Perugorria MJ; Bujanda L; Lammert F; Banales JM
    Surg Obes Relat Dis; 2016 Dec; 12(10):1838-1846. PubMed ID: 27576208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
    Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
    J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term hypercaloric diet exacerbates metabolic liver disease in PNPLA3 I148M animals.
    Su H; Haque M; Becker S; Edlund K; Duda J; Wang Q; Reißing J; Marschall HU; Candels LS; Mohamed M; Sjöland W; Liao L; Drexler SA; Strowig T; Rahnenführer J; Hengstler JG; Hatting M; Trautwein C
    Liver Int; 2023 Aug; 43(8):1699-1713. PubMed ID: 37073116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.
    Lindén D; Ahnmark A; Pingitore P; Ciociola E; Ahlstedt I; Andréasson AC; Sasidharan K; Madeyski-Bengtson K; Zurek M; Mancina RM; Lindblom A; Bjursell M; Böttcher G; Ståhlman M; Bohlooly-Y M; Haynes WG; Carlsson B; Graham M; Lee R; Murray S; Valenti L; Bhanot S; Åkerblad P; Romeo S
    Mol Metab; 2019 Apr; 22():49-61. PubMed ID: 30772256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
    Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M
    J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.
    Wang CW; Lin HY; Shin SJ; Yu ML; Lin ZY; Dai CY; Huang JF; Chen SC; Li SS; Chuang WL
    Liver Int; 2011 Oct; 31(9):1326-31. PubMed ID: 21745282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea.
    Lee SS; Byoun YS; Jeong SH; Woo BH; Jang ES; Kim JW; Kim HY
    Dig Dis Sci; 2014 Dec; 59(12):2967-74. PubMed ID: 25069572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.
    Karamfilova V; Gateva A; Assyov Y; Alexiev A; Savov A; Yaneva N; Ivanova I; Ivanova-Boyanova R; Ivanova R; Vlahova Z; Mateva L; Kamenov Z
    J Gastrointestin Liver Dis; 2019 Dec; 28(4):433-438. PubMed ID: 31826069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B.
    Viganò M; Valenti L; Lampertico P; Facchetti F; Motta BM; D'Ambrosio R; Romagnoli S; Dongiovanni P; Donati B; Fargion S; Colombo M
    Hepatology; 2013 Oct; 58(4):1245-52. PubMed ID: 23564580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PNPLA3 I148M polymorphism and progressive liver disease.
    Dongiovanni P; Donati B; Fares R; Lombardi R; Mancina RM; Romeo S; Valenti L
    World J Gastroenterol; 2013 Nov; 19(41):6969-78. PubMed ID: 24222941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.
    Ericson E; Bergenholm L; Andréasson AC; Dix CI; Knöchel J; Hansson SF; Lee R; Schumi J; Antonsson M; Fjellström O; Nasr P; Liljeblad M; Carlsson B; Kechagias S; Lindén D; Ekstedt M
    Hepatol Commun; 2022 Oct; 6(10):2689-2701. PubMed ID: 35833455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
    Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
    Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.
    Liu WY; Zheng KI; Pan XY; Ma HL; Zhu PW; Wu XX; Rios RS; Targher G; Byrne CD; Wang XD; Chen YP; Zheng MH
    J Gastroenterol Hepatol; 2020 Jun; 35(6):1057-1064. PubMed ID: 31677195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of PNPLA3 I148M with Liver Disease Biomarkers in Latinos.
    Roe JD; Garcia LA; Klimentidis YC; Coletta DK
    Hum Hered; 2021; 86(1-4):21-27. PubMed ID: 34749354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.